SpringerLink
Log in

Neue Aspekte in der Therapie von Schilddrüsenkarzinomen

Highlights des ASCO-Kongresses 2016

New aspects in the treatment of thyroid cancer

Highlights of the ASCO Annual Meeting 2016

  • Leitthema
  • Published:
HNO Aims and scope Submit manuscript

Zusammenfassung

Anfang Juni 2016 fand in Chicago der jährliche Kongress der American Society of Clinical Oncology (ASCO) statt. In diesem Jahr wurden insgesamt 28 Studien zur Therapie von Patienten mit Schilddrüsenkarzinomen vorgestellt, die im vorliegenden Beitrag nach dem Grad der Differenzierung vorgestellt werden. Die am häufigsten durchgeführte kurative Therapiemodalität ist nach wie vor die chirurgische Behandlung. Im Rahmen eines palliativen Konzepts hingegen finden vermehrt Kinaseinhibitoren Anwendung. Der neueste Stand der Wissenschaft zur Therapie von Schilddrüsenkarzinomen, sowohl chirurgisch als auch internistisch-onkologisch, wird in diesem Review zusammengefasst.

Abstract

The annual meeting of the American Society of Clinical Oncology (ASCO) took place at the beginning of June 2016 in Chicago. This year a total of 28 studies on the treatment of patients with thyroid cancer were presented, described in this review article according to the degree of cancer cell differentiation. The leading curative treatment modality is still surgery. In contrast, kinase inhibitors are being used increasingly within palliative concepts. The latest state of the art of thyroid cancer treatment, both surgical and medical, is summarized in this review.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Mikhael A, Patell R, Bhuchar G, Tabet M, Bena J, Morrison S, Berber E, Ergin AB, Nwizu TI, Nasr C (2016) Chest X‑ray prior to thyroidectomy: Is it really needed? J Clin Oncol 34 (suppl):6092

  2. Bhuchar G, Niwattisaiwong S, Patell R, Patel J, Berber E, Tabet M, Nwizu TI, Bena J, Nasr C (2016) Does margin status affect oncologic outcomes and survival in patients with papillary thyroid cancer? J Clin Oncol 34 (suppl):6097

  3. Keegan THM, Brunson A, Semrad A, Farwell G, Semrad TJ (2016) Predictors of neck reoperation (NRO) in 35,538 Californians with differentiated thyroid cancer. J Clin Oncol 34 (suppl):6093

  4. Kuba S, Yamanouchi K, Hayashida N, Maeda S, Sakimura C, Kawakami F, Yano H, Matsumoto M, Otsubo R, Sato S, Fujioka H, Kuroki T, Nagayasu T, Eguchi S (2016) Total thyroidectomy versus thyroid lobectomy for papillary thyroid cancer: comparative analysis after propensity score matching – a multicenter study. J Clin Oncol 34 (suppl):e17556

  5. Patell R, Bhuchar G, Tabet M, Bena J, Morrison S, Berber E, Ergin AB, Nwizu TI, Nasr C (2016) Utility or futility of preoperative thyroglobulin in patients undergoing thyroidectomy for differentiated thyroid cancer. J Clin Oncol 34 (suppl):6098

  6. Xu JY, Zaidi TM, Cote GJ, Hu MI-N, Waguespack SG, Cabanillas ME, Ying AK, Busaidy NL, Habra MA, Shanbhag N, Truong D, Yu RK, Shete S, Katz RL, Sherman SI (2016) Accurate detection of circulating tumor cells (CTCs) in patients with metastatic papillary thyroid cancer (MPTC) via an interphase fluorescence in situ hybridization (IFISH) assay. J Clin Oncol 34 (suppl):e17550

  7. Dunn L, Sherman EJ, Baxi SS, Grewal RK, Pentlow KS, Haque S, Tuttle RM, Sabra M, Fish S, Boucai L, Ni A, Knauf J, Pfister DG, Fagin JA, Ho AL (2016) Enhancing radioiodine (RAI) incorporation into BRAFV600E-mutant, RAI-refractory thyroid cancers with the BRAF inhibitor vemurafenib: A pilot study. J Clin Oncol 34 (suppl):6099

  8. Besic N, Petric R, Gazic B, Goricar K, Dolzan V (2016) Expression of miRNA and occurrence of distant metastases in patients with Hurthle cell carcinoma. J Clin Oncol 34 (suppl):e17554

  9. Manohar P, Brandel D, Bellile EL, Worden FP, Avram AM (2016) FDG PET/CT imaging for prognosis of metastatic non-iodine avid differentiated thyroid cancer. J Clin Oncol 34 (suppl):e17555

  10. Ibrahim RD, Kelany MR, Michael Elsayed MMMZ (2016) Low-dose versus high dose radioactive iodine ablation differentiated thyroid carcinoma: a prospective randomized study. J Clin Oncol 34 (suppl):6087

  11. Bhuchar G, Patell R, Desai D, Mikhael A, Nwizu TI, Shrikanthan S, Bena J, Nasr C (2016) Metastases from differentiated thyroid cancer – the Cleveland clinic experience. J Clin Oncol 34 (suppl):e17546

  12. Sherman EJ, Romesser PB, Ho AL, Baxi SS, Riaz N, McBride SM, Chan S, Tuttle RM, Pfister DG, Lee NY (2016) Radiation therapy and low dose doxorubicin in thyroid cancer: a phase II study. J Clin Oncol 34 (suppl):6100

  13. de Souza JA, Karrison T, Libao B, Worden FP, Krzyzanowska M, Hayes DN, Winquist E, Saloura V, Villaflor VM, Seiwert TY, Stadler WM, Cohen EEW, Schechter RB, Vokes EE (2016) Randomized phase 2 trial of cediranib alone or cediranib plus lenalidomide in iodine 131-refractory differentiated thyroid cancer (DTC): A University of Chicago Phase 2 Consortium trial. J Clin Oncol 34 (suppl):6013

  14. Zhu J, Huang Z, Wu W (2016) Recombinant human adenovirus p53 injection enhanced sensitivity of chemotherapeutics through DNA damage response pathway in advanced papillary thyroid cancer in vitro and in vivo. J Clin Oncol 34 (suppl):e17560

  15. Park TJ, Choi YW, Kim J‑H, Lim IK (2016) Strong immunoexpression of midkine is associated with multiple lymph node metastases in BRAFV600E papillary thyroid carcinoma. J Clin Oncol 34 (suppl):e17552

  16. Oven Ustaalioglu BB, Kilicoglu ZG, Canberk S, Tatoglu MT, Yildirim E, Bilici A (2016) The relationship between PET-CT images and histopathological features of thyroid incidenteloma, detected during follow-up of primary malignancy. J Clin Oncol 34 (suppl):e17565

  17. Pena CE, Wilhelm S, Meinhardt G, Schlumberger M, Brose MS (2016) Biomarkers of prognosis in patients with differentiated thyroid cancer: results from the DECISION trial. J Clin Oncol 34 (suppl):6059

  18. Matos I, Grau JJ, Grande E, Martinez Trufero J, Trigo JM, Lopez C, Manzano JL, Reig O, Alvarez C, Beltran M, Duran M, Aller J, Iglesias L, Arevalo S, Manzano A, Mesia R, Reina JJ, Sepulveda JM, Virizuela J, Capdevila J (2016) Efficacy of multikinase inhibitors (MKIs) in successive treatment lines of refractory advanced thyroid cancer patients (pts). J Clin Oncol 34 (suppl):e17553

  19. Mehnert JM, Varga A, Brose M, Aggarwal RR, Lin C‑C, Prawira A, de Braud F, Tamura K, Doi T, Piha-Paul SA, Gilbert J, Saraf S, Thanigaimani P, Cheng JD, Keam B (2016) Pembrolizumab for advanced papillary or follicular thyroid cancer: preliminary results from the phase 1b KEYNOTE-028 study. J Clin Oncol 34 (suppl):6091

  20. Takahashi S, Kiyota N, Yamazaki T, Chayahara N, Nakano K, Inagaki L, Toda K, Enokida T, Minami H, Imamura Y, Sasaki T, Suzuki T, Fu**o K, Dutcus C, Tahara M (2016) Phase II study of lenvatinib in patients with differentiated, medullary, and anaplastic thyroid cancer: Final analysis results. J Clin Oncol 34 (suppl):6088

  21. Gianoukakis AG, Mathias EG, Dutcus C, Kalantari P, Yoon S (2016) Response to lenvatinib treatment in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC): updated results from SELECT. J Clin Oncol 34 (suppl):6089

  22. Sandulache V, Williams MD, Lai SY, Lu C, William WN, Busaidy NL, Cabanillas ME (2016) Clinical genomic testing of anaplastic thyroid carcinoma (ATC) and need for integration into future prospective clinical trials. J Clin Oncol 34 (suppl):6085

  23. Khan SA, Ci B, Gerber DE, McFadden DG, Beg MS, **: a pilot study. J Clin Oncol 34 (suppl):e17549

  24. Sun Y, Chi Y, Tang P, Gao M, Ji Q, Li Z, Zhang Y, Guo Z, Wang J, Chen X (2016) Phase II study of anlotinib for treatment of advanced medullary thyroid carcinoma. J Clin Oncol 34 (suppl):6015

Download references

Author information

Authors and Affiliations

  1. Univ.-Klinik für HNO-Heilkunde, Kopf-Hals-Chirurgie und Onkologie, Universitätsklinikum Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Deutschland

    B. B. Lörincz Ph.D., N. Möckelmann & R. Knecht

  2. Service d’ORL et chirurgie cervico-faciale, CHUV, Lausanne, Schweiz

    C. Simon

Authors
  1. B. B. Lörincz Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Simon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. N. Möckelmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R. Knecht
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to B. B. Lörincz Ph.D..

Ethics declarations

Interessenkonflikt

B.B. Lörincz, C. Simon, N. Möckelmann und R. Knecht geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Additional information

B.B. Lörincz ist Vorstand der Arbeitsgemeinschaft für Speicheldrüsen- und Schilddrüsenerkrankungen der Deutschen Gesellschaft für Hals-Nasen-Ohrenheilkunde, Kopf- und Hals-Chirurgie e. V., Bonn.

B.B. Lörincz und C. Simon teilen sich die Erstautorenschaft.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lörincz, B.B., Simon, C., Möckelmann, N. et al. Neue Aspekte in der Therapie von Schilddrüsenkarzinomen. HNO 64, 736–740 (2016). https://doi.org/10.1007/s00106-016-0246-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00106-016-0246-3

Schlüsselwörter

Keywords

Search

Navigation